Core Insights - IQVIA Holdings, Inc. (IQV) has outperformed the industry with a 25.5% increase over the past three months compared to the industry's 12.1% rise [1] - The company has a projected long-term EPS growth rate of 8.38%, with expected year-over-year earnings growth of 6.9% in 2025 and 8.4% in 2026 [1] Company Performance - IQVIA's R&DS backlog reached $32.4 billion in Q3 2025, reflecting a 4.1% year-over-year increase, with $8.1 billion expected to convert to revenues in the next 12 months [4][5] - The book-to-bill ratio was 1.15X in Q3 and 1.12X on a trailing-12-month basis, indicating that bookings are outpacing revenue recognition [5] - Net new bookings totaled $2.6 billion, with a 13% year-over-year growth in R&DS net bookings, alongside a 20% year-over-year increase in RFP activity, suggesting strong client demand [5][6] Strategic Partnerships - The collaboration with Amazon Web Services (AWS) as its Preferred Agentic Cloud Provider enhances IQVIA's capabilities in clinical trial automation and advanced analytics, positioning the company favorably in the life sciences and AI sectors [3] Shareholder Value - IQVIA has actively engaged in share repurchase programs, repurchasing $1.35 billion in 2024 and $1.03 billion over the nine months ending in 2025, which reduces the outstanding share count and signals management's confidence in the stock's intrinsic value [7]

Core Insights - IQVIA Holdings is positioned as a leader in healthcare information, real-world evidence collection, and AI-enabled trials and commercialization, distinguishing itself from traditional contract research organizations (CROs) [1] Group 1: Company Overview - IQVIA Holdings operates beyond the scope of a typical large CRO, emphasizing its extensive capabilities in healthcare information and advanced trial methodologies [1] Group 2: Investment Perspective - The company is viewed as a resilient investment opportunity, appealing to investors focused on long-term growth and income generation through a blend of dividend-paying equities and selective growth strategies [1]

Group 1 - IQVIA Holdings is positioned as a leader in healthcare information, real-world evidence collection, and AI-enabled trials and commercialization, distinguishing itself from traditional contract research organizations (CROs) [1] - The company operates in a competitive landscape where other CROs are vying for market share, but IQVIA's scale and capabilities provide a significant advantage [1] Group 2 - The investor profile mentioned indicates a focus on building a resilient, income-generating portfolio with a long-term growth mindset, blending dividend-paying equities, REITs, and selective growth opportunities [1] - The investment strategy emphasizes disciplined, fundamentals-driven investing, prioritizing capital preservation while compounding returns over time [1]

Core Insights - IQVIA Holdings Inc. is a significant player in the life sciences industry, providing clinical research services and healthcare intelligence, with a market cap of $38.4 billion [1][2] Company Overview - The company operates through three main segments: Technology & Analytics (TAS), Research & Development (R&DS), and Contract Sales & Medical Solutions (CSMS) [1] - IQVIA is categorized as a large-cap stock, reflecting its substantial size and influence in the diagnostics and research industry [2] Stock Performance - IQVIA's stock reached a 52-week high of $234.29 on November 25 and is currently trading 3% below that peak [3] - Over the past three months, IQVIA's stock prices have increased by 23.1%, outperforming the S&P 500 Index, which gained 6.2% during the same period [3] - Year-to-date, IQVIA's stock has gained 15.6%, while over the past 52 weeks, it has increased by 13%, compared to the S&P 500's gains of 16.5% and 13.2%, respectively [4] Financial Performance - Following the release of better-than-expected Q3 results on October 28, IQVIA's stock saw a slight uptick [5] - The company reported a 5.2% year-over-year growth in topline revenue, reaching $4.1 billion, which exceeded market expectations [5] - Adjusted EPS grew by 5.6% year-over-year to $3.00, surpassing consensus estimates by 1.4% [5] Competitive Position - IQVIA has outperformed its peer Agilent Technologies, Inc., which recorded 11.1% gains year-to-date and 7.2% returns over the past year [6]

Core Insights - IQVIA Holdings Inc. is valued at $37.6 billion and provides healthcare research services, including analytics, technology solutions, and clinical research to the life sciences industry, aimed at improving healthcare outcomes for patients [1] Performance Overview - Over the past year, IQV shares have gained 12.2%, underperforming the S&P 500 Index, which increased by nearly 13.7% [2] - In 2025, IQV's stock rose 10%, while the S&P 500 saw a 13.4% rise on a year-to-date basis [2] - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 7% over the past year, IQV's performance is relatively better, although the ETF's 10.3% year-to-date returns outshine IQV's gains [3] Financial Results - For Q3, IQV reported an adjusted EPS of $3, exceeding Wall Street expectations of $2.96, and revenue of $4.10 billion, beating forecasts of $4.07 billion [4] - The company expects full-year adjusted EPS to be in the range of $11.85 to $11.95 and revenue between $16.2 billion and $16.3 billion [4] Analyst Expectations - Analysts project IQV's EPS to grow by 5.1% to $10.77 for the current fiscal year ending in December [5] - Among 22 analysts covering IQV, the consensus rating is a "Strong Buy," with 16 "Strong Buy" ratings, one "Moderate Buy," and five "Holds" [5] - A month ago, the bullish sentiment increased, with 15 analysts suggesting a "Strong Buy" [6] Price Targets - BMO Capital initiated coverage of IQV with an "Outperform" rating and a price target of $260, indicating a potential upside of 20.3% from current levels [6] - The mean price target is $244.38, representing a 13.1% premium to current prices, while the highest price target of $265 suggests an upside potential of 22.6% [6]

Financial Performance - The company reported third quarter financial results at the high end of its guidance, indicating strong performance [1] - Guidance for the remainder of the year suggests over 5% revenue growth [1] Business Development - The company booked $2.6 billion in new business within its clinical segment during the third quarter, reflecting a healthy book-to-bill ratio of 1.15 [2] - There was a significant increase in request for proposals, which rose by 20% in dollars year-over-year [3] Market Trends - Decision timelines in the industry have started to normalize after a period of uncertainty, suggesting a recovery in the market [3] - The company believes that the end of 2024 and the beginning of 2025 likely represent the trough of the recent cycle [3]

Summary of IQVIA Holdings Conference Call Company Overview - **Company**: IQVIA Holdings (NYSE:IQV) - **Industry**: Healthcare, specifically focused on clinical research and data analytics for the pharmaceutical sector Key Financial Highlights - **Third-Quarter Results**: Reported financial numbers at the high end of guidance, with over 5% revenue growth expected for the year [2][30] - **New Business Bookings**: $2.6 billion in new business booked in the clinical segment, with a book-to-bill ratio of 1.15 [2][3] - **Request for Proposals (RFPs)**: Increased by 20% year-over-year, indicating strong demand [2][14] Industry Dynamics - **Market Recovery**: The period of uncertainty in the pharmaceutical industry is lifting, with decision timelines returning to normal [3][9] - **Impact of COVID-19**: The industry experienced overspending and overinvestment during the pandemic, leading to a subsequent decline in capital availability for emerging biotech [5][6] - **Cancellations of Clinical Trials**: Elevated cancellations due to economic reasons and uncertainty have largely subsided [6][7] Macro Environment - **Regulatory Changes**: The Inflation Reduction Act (IRA) and other macro events created uncertainty, affecting large pharma's investment decisions [6][9] - **FDA Changes**: Leadership changes and unclear policies at the FDA contributed to a difficult environment for investment [7][9] Business Segments and Trends - **R&D Spend Growth**: Long-term growth forecast for the top 15 pharma companies is around 3% annually, while the Emerging Biopharma (EBP) segment is expected to grow 8-10% per year [21][22] - **TADs Business**: Comprises three main parts: data business (low growth), real-world evidence (double-digit growth), and analytics/consulting (mid-single digits) [26][27] - **Pricing Environment**: Stabilized after a period of volatility, with no significant pricing pressures currently reported [20] Strategic Partnerships - **Agreement with Veeva**: Resolved long-standing disputes to enhance collaboration, reflecting the need for integration between data and technology applications in the pharma ecosystem [28][29] Future Outlook - **2026 Growth Expectations**: Anticipated to deliver at least 5% growth, with a long-term growth target of 6-9% [30][32] - **EBITDA Margins**: Expected to remain flat with a potential for 30 basis points of expansion annually, influenced by business mix and operational efficiencies [32][36] Additional Insights - **Client Relationships**: Strong relationships with clients across the biopharma industry, contributing to confidence in future bookings and demand [12][36] - **Market Segmentation**: The market for EBP is larger than perceived, with opportunities in segments previously overlooked by IQVIA [18] This summary encapsulates the key points discussed during the IQVIA Holdings conference call, highlighting the company's performance, industry trends, and future outlook.

Industry Overview - Companies in the drug development inputs and services sector are essential to the pharmaceutical and biotechnology value chain, providing support for drug discovery, preclinical testing, and manufacturing [2] - The industry benefits from stable demand as pharmaceutical companies often outsource non-core functions with medium to long-term contracts [2] - Future growth is expected due to increasing investments in biologics, cell and gene therapies, and advancements in precision medicine, which will drive demand for sophisticated tools and services [2] - There is a trend towards outsourcing in drug development for increased nimbleness and cost efficiency [2] - Potential challenges include pricing pressures from healthcare cost containment efforts and an evolving regulatory environment that could slow innovation or client activity [2] Q3 Earnings Performance - The seven tracked drug development inputs and services stocks reported strong Q3 results, with revenues exceeding analysts' consensus estimates by 3.1% [3] - On average, share prices of these companies have increased by 2% since the latest earnings results [3] Company-Specific Highlights - IQVIA (NYSE:IQV) reported revenues of $4.1 billion, reflecting a year-on-year increase of 5.2%, which surpassed analysts' expectations by 0.5% [5] - Despite the revenue growth, IQVIA's performance was mixed, with constant currency revenue aligning with analysts' estimates [5] - IQVIA delivered the weakest performance against analyst estimates within the group, resulting in a 3% decline in stock price since reporting, currently trading at $211 [6] - Medpace (NASDAQ:MEDP) was highlighted as the best performer in Q3, providing outsourced clinical trial management and research services [7]

Core Insights - IQVIA Holdings reported revenue of $4.1 billion for the quarter ended September 2025, reflecting a year-over-year increase of 5.2% and an EPS of $3.00, up from $2.84 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $4.07 billion by 0.86%, while the EPS also surpassed the consensus estimate of $2.96 by 1.35% [1] Financial Performance Metrics - The backlog stood at $32.40 billion, slightly below the average estimate of $32.49 billion from two analysts [4] - Revenue from Technology & Analytics Solutions was reported at $1.63 billion, compared to the average estimate of $1.66 billion, marking a 5% year-over-year increase [4] - Revenue from Research & Development Solutions reached $2.26 billion, exceeding the estimated $2.23 billion, with a year-over-year change of 4.5% [4] - Revenue from Contract Sales & Medical Solutions was $209 million, surpassing the average estimate of $180.27 million, representing a significant year-over-year increase of 16.1% [4] - Segment profit for Technology & Analytics Solutions was $370 million, below the average estimate of $412.55 million [4] - Segment profit for Contract Sales & Medical Solutions was reported at $13 million, significantly higher than the estimated $0.84 million [4] - Segment profit for Research & Development Solutions was $496 million, slightly above the average estimate of $495.9 million [4] Stock Performance - IQVIA shares have returned +20.3% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Revenue Performance - For Q3 2025, total revenues reached $3,896 million, an increase of $204 million or 5.2% compared to Q3 2024, driven by constant currency revenue growth of approximately $150 million or 3.9%[98] - For the first nine months of 2025, revenues increased to $11,946 million, up $499 million or 4.4% from the same period in 2024, with constant currency growth of approximately $418 million or 3.7%[99] - For the third quarter of 2025, total revenues increased to $4,100 million, up 5.2% from $3,896 million in the same period of 2024[115] - Technology & Analytics Solutions reported revenues of $1,631 million for Q3 2025, a 5.0% increase from $1,554 million in Q3 2024, driven by growth in the Americas region[118] - Research & Development Solutions achieved revenues of $2,260 million in Q3 2025, reflecting a 4.5% increase from $2,162 million in Q3 2024, primarily due to growth in the Americas region[129] - Contract Sales & Medical Solutions' revenues for Q3 2025 were $209 million, an increase of $29 million, or 16.1%, compared to Q3 2024[138] - For the first nine months of 2025, revenues reached $578 million, up $37 million, or 6.8%, from the same period in 2024[139] Cost and Expenses - Cost of revenues for Q3 2025 was $2,727 million, representing 66.5% of revenues, an increase of $209 million from Q3 2024, with a constant currency increase of approximately $183 million or 7.3%[100] - Selling, general and administrative expenses for Q3 2025 were $514 million, accounting for 12.5% of revenues, a decrease of $8 million from Q3 2024[102] - Depreciation and amortization for Q3 2025 was $286 million, or 7.0% of revenues, reflecting an increase of $8 million compared to Q3 2024[105] - Restructuring costs for Q3 2025 were $20 million, down from $28 million in Q3 2024, as the company continues to streamline operations[106] - Technology & Analytics Solutions' cost of revenues increased by $252 million, or 9.3%, in the first nine months of 2025 compared to the same period in 2024[122] - Research & Development Solutions' selling, general and administrative expenses increased by $10 million, or 4.5%, in Q3 2025 compared to Q3 2024[135] - Cost of revenues, exclusive of depreciation and amortization, increased by $27 million, or 17.5%, in Q3 2025 compared to Q3 2024[141] - In the first nine months of 2025, cost of revenues rose by $37 million, or 8.0%, compared to the same period in 2024[142] - Selling, general and administrative expenses increased by $1 million, or 7.1%, in Q3 2025, but decreased by $2 million, or 4.4%, in the first nine months of 2025[144][145] Financial Position - The company had a cash balance of $1,814 million as of September 30, 2025, an increase from $1,702 million as of December 31, 2024[148] - Net cash provided by operating activities was $1,919 million for the first nine months of 2025, an increase of $88 million compared to the same period in 2024[159] - Cash used in investing activities was $(1,201) million for the first nine months of 2025, an increase of $67 million compared to the same period in 2024[160] - Cash used in financing activities increased by $182 million to $(685) million during the first nine months of 2025 compared to the same period in 2024[161] - The company repurchased 6.4 million shares for $1,032 million under its equity repurchase program during the nine months ended September 30, 2025[151] Current and Noncurrent Liabilities - Total current assets as of September 30, 2025, decreased to $599 million from $935 million as of December 31, 2024, representing a decline of approximately 36%[168] - Total current liabilities increased to $5,120 million as of September 30, 2025, from $3,792 million as of December 31, 2024, marking an increase of about 35%[168] - Total noncurrent liabilities slightly decreased to $12,223 million as of September 30, 2025, from $12,333 million as of December 31, 2024[168] - Amounts due from subsidiaries that are non-Guarantors decreased to $4,663 million as of September 30, 2025, from $4,952 million as of December 31, 2024, a decline of about 6%[168] - Amounts due to subsidiaries that are non-Guarantors increased to $7,190 million as of September 30, 2025, from $6,341 million as of December 31, 2024, an increase of approximately 13%[168] Income and Taxation - Consolidated segment profit for the first nine months of 2025 was $1,555 million, slightly down from $1,576 million in the same period of 2024[116] - The effective income tax rate for the first nine months of 2025 was 18.3%, compared to 16.8% in the same period of 2024, influenced by changes in the geographical mix of earnings[111] - Net income for the nine months ended September 30, 2025, was $117 million, significantly lower than $554 million for the twelve months ended December 31, 2024, representing a decrease of approximately 79%[168] - Income from operations for the nine months ended September 30, 2025, was $1,074 million, down from $1,259 million for the twelve months ended December 31, 2024, reflecting a decline of approximately 15%[168] Other Information - The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, each contributing to revenue growth[93] - Approximately 30% of revenues in the first nine months of 2025 were denominated in currencies other than the US dollar, impacting financial results due to exchange rate fluctuations[96] - The contracted backlog for Research & Development Solutions rose from $31.1 billion at the end of 2024 to $32.4 billion by September 30, 2025, with an expected $8.1 billion to convert to revenues in the next twelve months[128] - The company’s equity in earnings (losses) of unconsolidated affiliates showed a loss of $14 million for the first nine months of 2025, a decrease from the previous year[114] - The U.S. government's One Big Beautiful Bill Act is not expected to materially impact the company's consolidated financial statements for 2025[112] - There have been no material changes to critical accounting policies as previously disclosed in the 2024 Form 10-K[171] - The company does not have any material off-balance sheet arrangements[169]